Riskpilot← Back to searchSign inGet full accessPLUS PHARMACIES AS
ASActiveOrg 916278667Ramberg Terrasse 9, 3086 HolmestrandAnnen forebyggende helsetjeneste · NACE 86904Est. 20150 employeeswww.geiloapotek.no
Revenue 2022
NOK 0
EBITDA margin
—
+27% vs 2021
Equity ratio
-254.6%
Financial strength
Net profit 2022
NOK 37K
-94% vs 2021
| Revenue | NOK 0 | — |
| EBITDA | NOK -21K | +27% |
| Net profit | NOK 37K | -94% |
| Total assets | NOK 1,3M | -17% |
| Equity | NOK -3,4M | +1% |
| Employees | 0 | — |
Legal name
PLUS PHARMACIES AS
Org number
916278667
Legal form
Aksjeselskap
NACE code
86904 · Annen forebyggende helsetjeneste
Founded
23. november 2015
Share capital
NOK 30 000
Employees
0
VAT registered
No
Audit selected
No
Last report
2022-12-31
Financial year
January – December
Signatory rights
Daglig leder alene. Daglig leder og styrets leder i fellesskap.
Company purpose
Eie aksjer i andre selskaper og sammenslutninger, samt andre aktiviteter i sammenheng med dette. Drive konsulentvirksomhet og rådgivning innen helse og aktivitet.
Address
Ramberg Terrasse 9, 3086 Holmestrand
Website
www.geiloapotek.no
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Revenue | 58 | 109 | 51 | 0 | 11 | 0 | 0 |
| Staff expenses | −0 | −241 | −305 | −0 | −0 | −0 | −0 |
| EBITDA | −2 | −1 089 | −358 | −2 230 | −15 | −29 | −21 |
| Depreciation & amort. | −0 | −0 | −0 | −0 | −0 | −32 | −0 |
| EBIT | −2 | −1 089 | −358 | −2 230 | −15 | −60 | −21 |
| Net financials | 0 | −40 | −43 | −41 | −217 | 669 | 58 |
| Profit before tax | −2 | −1 129 | −400 | −2 272 | −232 | 609 | 37 |
| Tax | −0 | −0 | −0 | −0 | −0 | −0 | −0 |
| Net profit | −2 | −1 129 | −400 | −2 272 | −232 | 609 | 37 |
| Item | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 |
|---|---|---|---|---|---|---|---|
| Total assets | 126 | 706 | 2 430 | 1 399 | 1 184 | 1 590 | 1 320 |
| Equity | 28 | −1 102 | −1 502 | −3 774 | −4 006 | −3 397 | −3 360 |
| Long-term debt | 0 | 0 | 0 | 333 | 5 190 | 4 026 | 2 680 |
| Short-term debt | 98 | 1 808 | 3 932 | 4 840 | 0 | 961 | 2 000 |
| Total debt | 98 | 1 808 | 3 932 | 5 173 | 5 190 | 4 987 | 4 680 |
EBITDA margin
-2090200.0%
This company
15.8%
Market median
-13229214% vs market
20162022
Equity ratio
-254.6%
This company
38.2%
Market median
-766% vs market
20162022
Return on equity
3695900.0%
This company
18.4%
Market median
+20086313% vs market
20162022
Net profit margin
3695900.0%
This company
8.1%
Market median
+45628295% vs market
20162022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20162022
Debt / equity
1.39×
This company
0.62×
Market median
-124% vs market
20162022
- Annual report 2022Filed via Brønnøysundsregistrene · Period 2022-01-01 – 2022-12-31
- Annual report 2021Filed via Brønnøysundsregistrene · Period 2021-01-01 – 2021-12-31
- Annual report 2020Filed via Brønnøysundsregistrene · Period 2020-01-01 – 2020-12-31
- Annual report 2019Filed via Brønnøysundsregistrene · Period 2019-01-01 – 2019-12-31
- Annual report 2018Filed via Brønnøysundsregistrene · Period 2018-01-01 – 2018-12-31
- Annual report 2017Filed via Brønnøysundsregistrene · Period 2017-01-01 – 2017-12-31
- Annual report 2016Filed via Brønnøysundsregistrene · Period 2015-11-02 – 2016-12-31
| Name | Role | Member since | Age | Other directorships |
|---|---|---|---|---|
MA Chief Executive Officer | Chief Executive Officer | 2015 | — | — |
No data on file.
| Shareholder | Type | Ownership | Votes | Since |
|---|---|---|---|---|
| Individual | 10.0% | 10.0% | 2022 | |
| Individual | 10.0% | 10.0% | 2022 | |
| Individual | 10.0% | 10.0% | 2022 |
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
PLUS PHARMACIES AS 
SEMSBYEN APOTEK ASBoard members of PLUS PHARMACIES AS also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Mari-Mette Aasen | Chief Executive Officer | 0 companies |